

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: **0 526 004 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 92306137.8

(22) Date of filing: 02.07.92

(51) Int. Cl.⁵: **C07D 487/04, A61K 31/505,**
// (C07D487/04, 239:00,
231:00)

(30) Priority: 09.07.91 GB 9114760

(43) Date of publication of application:
03.02.93 Bulletin 93/05

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL PT
SE

(71) Applicant: **Pfizer Limited**
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)
(84) **GB**

(71) Applicant: **PFIZER INC.**
235 East 42nd Street
New York, N.Y. 10017-5755 (US)


(84) **BE CH DE DK ES FR GR IT LI LU NL PT SE AT**

(72) Inventor: **Bell, Andrew Simon**
67 Tormore Park
Deal, Kent (GB)
Inventor: **Terrett, Nicholas Kenneth**
St. Margaret's Cottage, Jubilee Road
Worth, Nr. Deal, Kent (GB)

(74) Representative: **Wood, David John**
PFIZER LIMITED, Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **Pyrazolopyrimidinone antianginal agents.**

(57) Compounds of formula:



and pharmaceutically acceptable salts thereof,
wherein

R¹ is H; C₁-C₃ alkyl optionally substituted with one or more fluoro substituents; or C₃-C₅ cycloalkyl; R² is H, or C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl; R³ is C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl; C₃-C₅ cycloalkyl; C₃-C₆ alkenyl; or C₃-C₆ alkynyl; R⁴ is C₁-C₄ alkyl optionally substituted with OH, NR⁵R⁶, CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkenyl optionally substituted with CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkanoyl optionally substituted with NR⁵R⁶; hydroxy C₂-C₄ alkyl optionally substituted with NR⁵R⁶; (C₂-C₃ alkoxy)C₁-C₂ alkyl optionally substituted with OH or NR⁵R⁶; CONR⁵R⁶; CO₂R⁷; halo; NR⁵R⁶; NHSO₂NR⁵R⁶; NHSO₂R⁸; or phenyl or heterocyclyl either of which is optionally substituted with methyl; R⁵ and R⁶ are each independently H or C₁-C₄ alkyl, or together with the nitrogen atom to which they are attached from a pyrrolidinyl, piperidino, morpholino, 4-(NR⁹)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy; R⁷ is H or C₁-C₄ alkyl; R⁸ is C₁-C₃ alkyl optionally substituted with NR⁵R⁶; and R⁹ is H; C₁-C₃ alkyl optionally substituted with phenyl; hydroxy C₂-C₃ alkyl; or C₁-C₄ alkanoyl; are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.


EP 0 526 004 A1

The invention relates to a series of pyrazolo[4,3-d]-pyrimidin-7-ones, which are potent and selective inhibitors of cyclic guanosine-3',5'-monophosphate phosphodiesterase (cGMP PDE), having utility in a variety of therapeutic areas including the treatment of various cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

The compounds of the invention exhibit selectivity for inhibition of cGMP PDEs rather than cyclic adenosine 3',5'-monophosphate phosphodiesterases (cAMP PDEs) and, as a consequence of this selective PDE inhibition, cGMP levels are elevated, which in turn can give rise to beneficial anti-platelet, anti-neutrophil, anti-vasospastic and vasodilatory activity, as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF) and nitrovasodilators. Thus the compounds have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).

European patent application EP-A-0201188 discloses certain pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists and PDE inhibitors, useful in the treatment of cardiovascular disorders such as heart failure or cardiac insufficiency. However these compounds are neither particularly potent PDE inhibitors, nor are they reported to be selective inhibitors of cGMP PDE.

The compounds of the present invention have the formula (I):



wherein

R¹ is H; C₁-C₃ alkyl optionally substituted with one or more fluoro substituents; or C₃-C₅ cycloalkyl;

R² is H, or C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl;

R³ is C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl; C₃-C₅ cycloalkyl; C₃-C₆ alkenyl; or C₃-C₆ alkynyl;

R⁴ is C₁-C₄ alkyl optionally substituted with OH, NR⁵R⁶, CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkenyl optionally substituted with CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkanoyl optionally substituted with NR⁵R⁶; hydroxy C₂-C₄ alkyl optionally substituted with NR⁵R⁶; (C₂-C₃ alkoxy)C₁-C₂ alkyl optionally substituted with OH or NR⁵R⁶; CONR⁵R⁶; CO₂R⁷; halo; NR⁵R⁶; NHSO₂NR⁵R⁶; NHSO₂R⁸; or phenyl or heterocyclyl either of which is optionally substituted with methyl;

R⁵ and R⁶ are each independently H or C₁-C₄ alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-(NR⁹)piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy;

R⁷ is H or C₁-C₄ alkyl;

R⁸ is C₁-C₃ alkyl optionally substituted with NR⁵R⁶;

and

R⁹ is H; C₁-C₃ alkyl optionally substituted with phenyl; hydroxy C₂-C₃ alkyl; or C₁-C₄ alkanoyl; and pharmaceutically acceptable salts thereof.

In the above definition, unless otherwise indicated, alkyl groups having three or more carbon atoms may be straight or branched chain. In addition alkenyl or alkynyl groups having four or more carbon atoms, or alkoxy groups having three carbon atoms, may be straight or branched chain. Halo means fluoro, chloro, bromo or iodo, whilst heterocyclyl is selected from thienyl, pyridyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl or pyrimidinyl.

The compounds of formula (I) may contain one or more asymmetric centres and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.

The compounds of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.

Also included in the invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.

The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids. Examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts. Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases. Examples include the sodium and potassium salts.

A preferred group of compounds of formula (I) is that wherein R^1 is H, methyl or ethyl; R^2 is C_1 - C_3 alkyl; R^3 is C_2 - C_3 alkyl; R^4 is C_1 - C_2 alkyl optionally substituted with OH, NR^5R^6 , $CONR^5R^6$ or CO_2R^7 ; acetyl optionally substituted with NR^5R^6 ; hydroxyethyl substituted with NR^5R^6 ; ethoxymethyl optionally substituted with OH or NR^5R^6 ; $CH=CHCN$; $CH=CHCONR^5R^6$; $CH=CHCO_2R^7$; CO_2H ; $CONR^5R^6$; Br; NR^5R^6 ; $NHSO_2NR^5R^6$; $NHSO_2R^8$; or pyridyl or imidazolyl either of which is optionally substituted with methyl; R^5 and R^6 are each independently H, methyl or ethyl, or together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-(NR^9)-1-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy; R^7 is H or t-butyl; R^8 is methyl or $CH_2CH_2CH_2NR^5R^6$; and R^9 is H, methyl, benzyl, 2-hydroxyethyl or acetyl.

A particularly preferred group of compounds of formula (I) is that wherein R^1 is methyl; R^2 is n-propyl; R^3 is ethyl or n-propyl; R^4 is $CH_2NR^5R^6$, $CH_2OCH_2CH_2NR^5R^6$, $CH_2OCH_2CH_3$, $CH_2OCH_2CH_2OH$, $COCH_2NR^5R^6$, $CH(OH)CH_2NR^5R^6$, $CH=CHCON(CH_3)_2$, $CH=CHCO_2R^7$, CO_2H , $CONR^5R^6$, Br, $NHSO_2NR^5R^6$, $NHSO_2CH_2CH_2CH_2NR^5R^6$, 2-pyridyl, 1-imidazolyl or 1-methyl-2-imidazolyl; R^5 and R^6 together with the nitrogen atom to which they are attached form a piperidino, 4-hydroxypiperidino, morpholino, 4-(NR^9)-1-piperazinyl or 2-methyl-1-imidazolyl group; R^7 is H or t-butyl; and R^9 is H, methyl, benzyl, 2-hydroxyethyl or acetyl.

Especially preferred individual compounds of the invention include:


5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-[5-(4-acetyl-1-piperazinyl)acetyl-2-ethoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.


Depending on the nature of R^4 , the compounds of formula (I) may be prepared by a variety of methods from a compound of formula (II):




wherein R^1 , R^2 and R^3 are as previously defined. For example, when R^4 is C_2 - C_4 alkanoyl, the required product is obtainable by conventional Friedel-Crafts acylation whereby (II) is reacted with about a 2-fold excess of an acyl halide of formula $(C_1$ - C_3 alkyl)COY, wherein Y is halo, preferably chloro or bromo, in the presence of about a 3-fold excess of a Lewis acid such as aluminium chloride or aluminium bromide, in a suitable solvent, e.g. dichloromethane, at from about 0°C to the reflux temperature of the reaction medium. When R^4 is C_2 - C_4 alkanoyl substituted with NR^5R^6 , wherein R^5 and R^6 are as previously defined, the product is obtained from (II) via the intermediacy of the corresponding haloketone, i.e. a compound of formula (I) wherein R^4 is $CO(C_1$ - C_3 alkylene)X and X is halo, preferably chloro or bromo, by reaction of the appropriate haloketone with the required amine of formula R^5R^6NH in the presence of at least one equivalent of base to scavenge the liberated acid by-product (HX), in a suitable solvent, e.g. acetonitrile, at about room temperature. The base may be an inorganic salt such as anhydrous potassium carbonate, a tertiary amine such as triethylamine, or excess reactant amine. In cases wherein either R^5 or R^6 is H, it may be advantageous to use a protected amine of formula R^5NHP or

R^6NHP wherein P is a compatible protecting group, e.g. benzyl which can be subsequently removed by catalytic hydrogenation. When both R^5 and R^6 are H, an ammonia equivalent of formula $P'NH$, wherein P' is a protecting group such as t-butoxycarbonyl, may be beneficially employed. In this case, the potassium salt of the non-basic aminating reagent is used for reaction with the haloketone; deprotection is effected by acidolysis using, for example, hydrogen chloride, which allows convenient isolation of the desired aminoketone as its hydrochloric salt. The intermediate haloketone is also obtained via Friedel-Crafts chemistry, as described above, in this case between (II) and the appropriate haloacyl halide of formula $X(C_1-C_3 \text{ alkylene})COY$, wherein X and Y are as previously defined.

The above ketones of general formula (IA):




wherein R^{10} is either H or NR^5R^6 , and R^1 , R^2 , R^3 , R^5 and R^6 are as previously defined, may be reduced to provide the corresponding alcohol derivatives of general formula (IB):




wherein R^1 , R^2 , R^3 and R^{10} are as previously defined. The reducing agent is preferably sodium borohydride and the reaction may be conducted in a suitable solvent, e.g. ethanol, at about room temperature.

A compound of formula (I) wherein R^4 is hydroxymethyl and R^1 , R^2 and R^3 are as previously defined may be prepared by subjecting a compound of formula (II) to standard chloromethylation conditions, e.g. paraformaldehyde and concentrated hydrochloric acid, at from about room temperature to about 120°C , to provide the intermediate chloromethyl derivative of formula (III), which is then treated with an alkali metal hydroxide, e.g. sodium hydroxide or potassium hydroxide, in a suitable solvent such as an ethylene glycol-dimethyl sulphoxide mixture at from about room temperature to about 100°C .



The above chloromethyl derivatives (III), wherein R^1 , R^2 and R^3 are as previously defined, are valuable intermediates in the synthesis of further compounds of formula (I). For example, treatment of (III) with C_2 - or C_3 - alkanol in the presence of about one equivalent of an alkali metal, preferably sodium, at about room temperature, affords the corresponding C_2 - or C_3 -alkoxymethyl derivatives respectively. Similarly, when a C_2 - or C_3 -diol is employed, the analogous hydroxy (C_2 - or C_3 -alkoxy)methyl compounds are obtained. The latter may be further transformed by activation of the terminal hydroxy group, e.g. by conventional mesylation using about a 10% excess of mesyl chloride, in pyridine as solvent, at from about 0°C to about room temperature, followed by reaction of the mesylate with, for example, an amine of formula $R^5R^6\text{NH}$. Preferably the reaction is conducted with up to a 5-fold excess of amine in a suitable solvent, e.g. acetonitrile, at the reflux temperature of the reaction medium. As discussed above, when either R^5 or R^6 is H or both are H, an amine protection-deprotection strategy may be profitably employed. Thus are provided compounds of formula (I) wherein R^4 is (C_2 - C_3)alkoxymethyl optionally substituted with either OH or NR^5R^6 , and R^1 , R^2 , R^3 , R^5 and R^6 are as previously defined.

The higher homologues of the above compounds, i.e. those compounds of formula (I) wherein R^4 is (C_2 - C_3)alkoxyethyl optionally substituted with either OH or NR^5R^6 , may be synthesised by similar procedures from the 2-chloroethyl, 2-bromoethyl or 2-mesyloxyethyl analogues of (III) which, in turn, are derivable from the corresponding 2-hydroxyethyl precursor by standard procedures. This precursor may be prepared for example from a compound of formula (I), wherein R^4 is bromo and R^1 , R^2 and R^3 are as previously defined (formula (IV)), by lithium-bromine exchange using *n*-butyllithium, followed by reaction of the aryllithium intermediate (*vide infra*) with ethylene oxide.



The chloromethyl intermediates of formula (III) may also be used for the preparation of compounds of formula (I), wherein R^4 is $\text{CH}_2\text{NR}^5\text{R}^6$ and R^1 , R^2 , R^3 , R^5 and R^6 are as previously defined, by reaction with the appropriate amine of formula $R^5R^6\text{NH}$ (or protected version thereof - *vide supra*). Preferably the reaction is carried out with about a 3-fold excess of amine in a suitable solvent, e.g. 2-butanone, at from about 0°C to the reflux temperature of the reaction medium. By analogy, compounds of formula (I) wherein R^4 is (C_2 - C_4 alkylene) NR^5R^6 may be conveniently obtained from the appropriate chloro, bromo, or mesyloxy precursor which, in turn, is derivable from the corresponding alcohol (see above for a synthetic approach to the 2-hydroxyethyl analogue). The 3-hydroxypropyl and 4-hydroxybutyl analogues may be prepared by catalytic hydrogenation of the alkenols obtained when the above-mentioned bromo compound of formula (IV) is subjected to Heck reaction conditions (*vide infra*) with allyl alcohol or 3-buten-1-ol respectively.

The chloromethyl intermediates may further be employed to furnish the corresponding methyl derivatives, i.e. compounds of formula (I) wherein R^4 is CH_3 and R^1 , R^2 and R^3 are as previously defined. This can be achieved by catalytic hydrogenation using a palladium on charcoal catalyst, in a suitable solvent such as ethyl acetate, at about 50 p.s.i. (3.45 bar) and room temperature. By analogy, when R^4 is ethyl, *n*-propyl or *n*-butyl, such compounds of formula (I) may also be obtained from the corresponding alkyl chlorides derived, in turn, from the appropriate alcohols mentioned above by standard methodology. Other alcohol derivatives, e.g. the corresponding bromide or mesylate, may also be used.

The above bromo derivatives (IV), which are valuable intermediates in the synthesis of yet further compounds of formula (I), may be prepared from a compound of formula (II) by direct bromination in a suitable solvent. This may be achieved, for example, either with about a 60% excess of *N*-bromosuccinimide in dimethylformamide at room temperature or with a similar excess of bromine in glacial acetic acid at from about room temperature to about 100°C . Alternatively, (IV) and the corresponding fluoro, chloro and iodo analogues may be obtained from the primary amine (*vide infra*) via classical sequential diazotisation-halogenation procedures including, for example, the Schiemann, Sandmeyer and Gatterman reactions.

By exploitation of Heck methodology, the bromo intermediate (IV) can be transformed to compounds of formula (I), wherein R^4 is $\text{CH}=\text{CHCN}$, $\text{CH}=\text{CHCONR}^5\text{R}^6$ or $\text{CH}=\text{CHCO}_2\text{R}^7$ and R^1 , R^2 , R^3 , R^5 , R^6 and R^7 are as previously defined, by employment of acrylonitrile or the appropriate acrylic acid amide or ester derivative.

The reaction is generally carried out with about a 50% excess of both the alkene reagent and a tertiary amine such as triethylamine, in the presence of about 0.1 equivalents of a tertiary arylphosphine, preferably tri-*o*-tolylphosphine, and about 0.05 equivalents of palladium(II) acetate, in a suitable solvent such as acetonitrile, at the reflux temperature of the reaction medium. The resulting acrylic esters may be hydrolysed if desired, e.g. using aqueous sodium hydroxide solution, with methanol as co-solvent, to afford the corresponding cinnamic acids. Moreover, all the alkenyl products thus synthesised may be subjected to catalytic hydrogenation, e.g. using 5% palladium on charcoal in a suitable solvent at about 15 p.s.i. (1.0 bar) and room temperature, to provide compounds of formula (I) wherein R⁴ is CH₂CH₂CN, CH₂CH₂CONR⁵R⁶ or CH₂CH₂CO₂R⁷ and R¹, R², R³, R⁵, R⁶ and R⁷ are as previously defined for formula (I). An alternative reduction strategy, in which the acrylonitrile derivative (cinnamionitrile analogue) is exhaustively hydrogenated with Raney nickel in glacial acetic acid, affords a compound of formula (I) wherein R⁴ is 3-aminopropyl and R¹, R² and R³ are as previously defined.

The higher homologues, i.e. compounds of formula (I) wherein R⁴ is either C₃-C₄ alkyl or C₃-C₄ alkenyl substituted with CN, CONR⁵R⁶ or CO₂R⁷, or is 4-aminobutyl, may be derived from the previously mentioned alkenols obtained from Heck reactions between the bromo compound of formula (IV) and either allyl alcohol or 3-buten-1-ol. The conventional procedures necessary for transformation of the terminal hydroxyl group via a suitably reactive derivative, e.g. the corresponding chloride, bromide or mesylate, to the required functional groups will be well known to persons skilled in the art, and will be equally applicable to the 2-hydroxyethyl analogue (*vide supra*) thereby offering an alternative to Heck methodology. Compounds of formula (I), wherein R⁴ is CH₂CN, CH₂CONR⁵R⁶, CH₂CO₂R⁷ or CH₂CH₂NH₂, may be obtained from the chloromethyl intermediates of formula (III) by reaction with an alkali metal cyanide, e.g. sodium cyanide or potassium cyanide, followed by standard transformations or the resulting nitrile.

As a general alternative to the above Heck reaction approach, the desired alkenes (and derived alkanes via catalytic hydrogenation) may be obtained using a Wittig-Horner strategy in which an aldehyde of formula (I), wherein R⁴ is CHO and R¹, R² and R³ are as previously defined, is reacted with the appropriate phosphonium salt or phosphonate in the presence of a suitable base. The aldehyde itself is obtainable for formylation, e.g. using dimethylformamide, of the previously described aryllithium derivative of (IV) and, by analogy, is also a convenient precursor to compounds of formula (I) wherein R⁴ is C₂-C₄ alkenyl or C₂-C₄ alkyl and R¹, R² and R³ are as previously defined.

This aryllithium intermediate is also useful in the preparation of compounds of formula (I) wherein R⁴ is CONR⁵R⁶ or CO₂R⁷ and R¹, R², R³, R⁵, R⁶ and R⁷ are as previously defined. For example, lithiation of (IV) in dry tetrahydrofuran at about -78°C using about a 5-fold excess of a solution of *n*-butyllithium in hexane, quenching of the resulting aryllithium with carbon dioxide at about -40°C, and aqueous work-up at about 0°C including careful acidification to pH 3, furnishes the corresponding benzoic acid derivative. The acid may be activated under mild conditions, such as those containing in peptide bond formation via amino acid coupling procedures, and converted to an ester or amide derivative as required. For example, activation of the benzoic acid using a carbodiimide/1-hydroxybenzotriazole combination in the presence of the required amine of formula R⁵R⁶NH or alcohol of formula R⁷OH, in a suitable solvent such as dichloromethane at about 0°C to room temperature, yields the corresponding amide or ester respectively.



The bromo intermediates of formula (IV) are also of utility in the synthesis of compounds of formula (I) wherein R⁴ is phenyl or heterocyclyl, each of which is optionally substituted with methyl, and R¹, R² and R³ are as previously defined. When R⁴ is phenyl or C-linked heterocyclyl, it may be introduced via palladium-catalysed coupling of the zincate derivative generated in situ from the corresponding phenyllithium or heterocyclyllithium intermediate; the latter, in turn, may be obtained from either the heterocycle or haloheterocycle as necessary by treatment with *n*-butyllithium. Thus, for example, the phenyllithium or heterocyclyllithium (in the presence of about 1 extra equivalent of *n*-butyllithium to accommodate the active hydrogen atom of the pyrazolopyrimidinone substrate) is treated with about 2 equivalents of anhydrous zinc chloride in dry tetrahydrofuran at about -78°C followed, at about room temperature, by (IV) and the palladium catalyst, preferably tetrakis(triphenylphosphine)palladium(0). The reaction mixture can be heated to reflux with addition of up to about 2 further equivalents of anhydrous zinc chloride if necessary. When R⁴ is N-linked heterocyclyl, the reaction may be conducted with up to about a 5-fold excess of the appropriate heterocycle in the presence of about a 10% excess of base, e.g. anhydrous potassium carbonate, to scavenge the hydrogen bromide by-product, together with about a 10% excess of copper-bronze and about 0.25 equivalents of iodine catalyst in a suitable solvent, e.g. dimethylformamide, at about the reflux temperature of the reaction medium.

Compounds of formula (I), wherein R⁴ is NHSO₂NR⁵R⁶ or NHSO₂R⁸ and R¹, R², R³, R⁵, R⁶ and R⁸ are as previously defined, may be synthesised from the corresponding primary amine which, in turn, is obtained by nitration of (II) using, e.g. a conventional concentrated nitric acid/concentrated sulphuric acid combination, followed by reduction of the nitroarene by catalytic hydrogenation using conventional procedures. The reaction is generally carried out using equimolar quantities of the primary amine of formula (I), wherein R⁴ is NH₂ and

R^1 , R^2 and R^3 are as previously defined, and either the required sulphamoyl halide or alkylsulphonyl halide (preferably the chlorides) of formula $R^5R^6NSO_2\text{halo}$ or $R^8SO_2\text{halo}$ respectively, in the presence of excess tertiary amine such as triethylamine or pyridine to scavenge the acid by-product, in a suitable solvent, e.g. dichloromethane, at from about 0°C to about room temperature. Pyridine may conveniently function as both base and solvent when desired, and the reaction may be optionally catalysed by the addition of about 0.1 to 0.2 equivalents of a 4-t-aminopyridine such as 4-dimethylaminopyridine. When both R^5 and R^6 are H, the desired product may also be obtained by reaction of the primary amine with sulphamide in a suitable solvent, e.g. 1,4-dioxan, at about 100°C .

When, in transformations of compounds of formula (II) to compounds of formula (I), R^3 is a group susceptible to reaction or removal under the particular conditions employed to introduce R^4 , said R^3 group may itself be introduced at the final stage of the synthesis. Thus a phenol of formula (II), wherein R^3 is H, and R^1 and R^2 are as previously defined, which is obtainable for example by Pd° -mediated deprotection of the O-allyl analogue, i.e. a compound of formula (II) wherein R^3 is allyl, and R^1 and R^2 are as previously defined, serves as the substrate for the subsequent reactions involved in introducing the various R^4 substituents. A final O-alkylation of the phenolic group is then necessary to furnish a compound of formula (I), wherein R^1 , R^2 , R^3 and R^4 are as previously defined. This may be achieved under standard conditions using the appropriate alkyl chloride, bromide or sulphonate in the presence of a base such as anhydrous potassium carbonate, in a suitable solvent, e.g. 2-butanone, at the reflux temperature of the reaction mixture. Alternatively, the alkylation may be effected under typical Mitsunobu reaction conditions.



A compound of formula (II) may be prepared from a compound of formula (V):




wherein R^1 , R^2 and R^3 are as previously defined, by the application of known cyclisation methods for pyrimidinone ring formation. Thus, for example, the cyclisation may be effected by the treatment of (V) with a base such as sodium hydroxide or potassium carbonate, optionally in the presence of hydrogen peroxide, in an ethanol-water medium at reflux temperature. Under these conditions the related nitrile of formula (VI), wherein R^1 , R^2 and R^3 are as previously defined, may also be employed as the precursor to (IV).

In an alternative cyclisation procedure, compounds of the formula (II) may be obtained by treatment of (V) with polyphosphoric acid at about 140°C .

Compounds of formulae (V) and (VI) may be prepared from compounds of formulae (VII) and (VIII) respectively:




wherein R^1 and R^2 are as previously defined, by reaction with a compound of formula (IX):



wherein R³ and Y are as previously defined.

10 The reaction is generally carried out using an excess of (IX) in the presence of an excess of a tertiary amine such as triethylamine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylaminopyridine, in an inert solvent such as dichloromethane at from about 0°C to room temperature.

15 Compounds of formula (I) may be obtained more directly from a compound of formula (X):



25 wherein R³, R⁴ and Y are as previously defined, when such acyl halides are readily accessible, by reaction with either (VII) or (VIII) and subsequent ring-closure of the product as described above. Clearly this alternative synthetic route will only be appropriate when R⁴ is compatible with the reaction conditions obtaining in both steps, e.g. when R⁴ is acetyl as illustrated by Example 17.

30 The aminopyrazoles of formulae (VII) and (VIII), the acyl halides of formulae (IX) and (X), and the intermediates employed for introduction of the various R⁴ substituents into compounds of formula (II) to afford compounds of formula (I), when neither commercially available nor subsequently described, can be obtained by conventional synthetic procedures, in accordance with literature precedent, from readily accessible starting materials using appropriate reagents and reaction conditions.

35 Certain of the compounds of formula (I), wherein R⁹ is as previously defined but not hydrogen, may be prepared directly from the corresponding 4-N-unsubstituted piperazine analogue, that is the precursor wherein R⁹ is hydrogen, using appropriate standard synthetic procedures.

40 All of the above reactions are entirely conventional and the necessary reagents and conditions for their performance can readily be established by reference to standard text books and to the Examples provided hereafter. Alternatives and variations will also be evident to persons skilled in the art to enable all the compounds defined by formula (I) to be prepared.

The biological activities of the compounds of the present invention were determined by the following test methods.

45 Phosphodiesterase activity

Compound affinities for cGMP and cAMP PDEs are assessed by determination of their IC₅₀ values (the concentration of inhibitor required for 50% inhibition of enzyme activity). The PDE enzymes are isolated from rabbit platelets and rat kidney, essentially by the method of W.J. Thompson *et al.* (Biochem., 1971, 10, 311).
 50 The calcium/calmodulin (Ca/CAM)-independent cGMP PDE and the cGMP-inhibited cAMP PDE enzymes are obtained from rabbit platelets whilst, of the four major PDE enzymes of the rat kidney, the Ca/CAM-dependent cGMP PDE (fraction I) is isolated. Assays are performed using a modification of the "batch" method of W.J. Thompson and M.M. Appleman (Biochem., 1979, 18, 5228). Results from these tests show that the compounds of the present invention are potent and selective inhibitors of both cGMP PDEs.

55 Platelet anti-aggregatory activity

This is assessed by the determination of a compound's ability to inhibit platelet aggregation *in vitro* induced

by platelet activating factor (PAF), and to potentiate the platelet antiaggregatory action in vitro of activators of guanylate cyclase such as nitroprusside and EDRF. Washed platelets are prepared essentially by the method of J.F. Mustard et al. (Methods in Enzymol., 1989, 169, 3) and aggregation is determined using standard turbidimetric techniques as described by G.V.R. Born, (J. Physiol. (Lond), 1962, 162, 67P).

Antihypertensive activity

This is assessed following intravenous or oral administration of a compound to spontaneously hypertensive rats. Blood pressure is recorded via a cannula implanted in the carotid artery of either conscious or anaesthetised animals.

For administration to man in the curative or prophylactic treatment of angina, hypertension or congestive heart failure, oral dosages of the compounds will generally be in the range of from 4-800 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 2-400 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal or sublingual administration will typically be within the range of from 1-400 mg per single dose as required. In practice the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.

For human use, the compounds of formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixtures with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.

Thus the invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

The invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for use in medicine.

The invention further provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS.

In a further aspect, the invention provides a method of treating or preventing stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS, in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.

The invention also includes any novel intermediates of formulae (II), (III) and (IV) disclosed herein.

The syntheses of the compounds of the invention and of the intermediates for use therein are illustrated by the following Examples and Preparations. The purity of the compounds was routinely monitored by thin layer chromatography (TLC) using Merck Kieselgel 60 F₂₅₄ plates. ¹H-Nuclear magnetic resonance spectra were recorded using either a Nicolet QE-300 or a Bruker AC-300 spectrometer and were in all cases consistent with the proposed structures.

EXAMPLE 1


5-(2-Ethoxy-5-piperidinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one





Piperidine (0.22 ml, 0.0022 mol) was added to a stirred suspension of 5-(5-bromoacetyl-2-ethoxyphenyl)-



1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3- d]pyrimidin-7-one (Preparation 8, 0.95 g, 0.0022 mol) and anhydrous potassium carbonate (0.6 g, 0.0044 mol) in acetonitrile (50 ml) at room temperature. After 18 hours the mixture was evaporated under vacuum, the residue dissolved in water (50 ml) and the solution extracted with ethyl acetate (3 x 30 ml). The organic extracts were combined, washed with brine (3 x 20 ml), dried (Na₂SO₄) and evaporated under vacuum. The resulting yellow solid was chromatographed on silica gel (12 g), using a methanol in dichloromethane elution gradient (0-2% methanol), to give an off-white solid. Crystallisation from ethyl acetate-hexane gave the title compound as an off-white powder (0.27 g, 28%), m.p. 149-151°C. Found: C,66.13; H,6.90; N,15.95. C₂₄H₃₁N₅O₅ requires C,65.88; H,7.14; N,16.01%.

EXAMPLES 2-8

The following Examples were prepared by the procedure of Example 1 using the appropriate amine.



Example	NR ⁵ R ⁶	% yield	m.p. (°C)	Analysis % (theoretical in brackets) C H N
2	$N(CH_2CH_3)_2$	4	120-121	65.21 7.31 16.37 (64.92 7.34 16.46)
3		23	183-185	62.48 6.62 17.32 (62.48 6.71 17.49)
4		29	159-160	63.20 6.58 15.87 (62.85 6.65 15.94)
5		21	202-204	61.84 6.12 18.68 (62.28 6.14 18.95) ^a
6		39	142-143	62.83 7.09 18.90 (63.00 6.90 19.16)

Example	NR ⁵ R ⁶	% yield	m.p. (°C)	Analysis % (theoretical in brackets) C H N
7		36	135-136	62.46 (62.22) 6.91 (7.10) 17.36 (17.41)
8		40	151-152	63.64 (63.56) 6.80 (6.89) 15.63 (15.44)


a 0.50 H₂O





EXAMPLE 9**5-[2-Ethoxy-5-[1-hydroxy-2-(1-piperazinyl)ethyl]phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one**

Sodium borohydride (0.01 g, 0.0027 mol) was added to a stirred suspension of 5-[2-ethoxy-5-(1-piperazinylacetyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.12 g, 0.0027 mol) in ethanol (10 ml) and the resulting solution stirred at room temperature for 18 hours. The solvent was removed by evaporation under vacuum, the residue suspended in saturated aqueous sodium carbonate solution (50 ml) and this mixture extracted with dichloromethane (3 x 20 ml). The organic extracts were combined, dried (Na₂SO₄) and evaporated under vacuum to give an oil. Trituration with ether gave a white solid, crystallisation of which from ethyl acetate-hexane gave the title compound as a white powder (0.050 g, 42%), m.p. 139-140°C. Found: C, 62.55; H, 7.44; N, 18.79. C₂₃H₃₂N₆O₃ requires C, 62.71; H, 7.32; N, 19.08%.

EXAMPLES 10-13

The following Examples were prepared by the procedure of Example 9 using the appropriate ketones (Examples 3, 4, 5 and 1 respectively).



Example	NR ⁵ R ⁶	% yield	m.p. (°C)	Analysis % (theoretical in brackets) C H N
10		37	139-141	61.92 7.01 17.08 (62.22 7.10 17.42)
11		69	125-127	62.23 7.10 15.53 (62.56 7.08 15.86)
12		77	221-222	63.68 6.39 19.17 (63.29 6.47 19.25)
13		97	117-118	65.51 7.57 15.84 (65.58 7.57 15.93)

EXAMPLE 14

1-Methyl-5-(5-morpholinoacetyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

This compound was prepared from morpholine and 5-(5-bromoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Preparation 11), following the procedure of Example 1, and was obtained as white crystals (47%), m.p. 128-129°C. Found: C, 63.62; H, 7.07; N, 15.53. $C_{24}H_{31}N_5O_4$ requires C, 63.56; H, 6.89; N, 15.44%.

EXAMPLE 15

1-Methyl-5-[5-(4-methyl-1-piperazinylacetyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

This compound was prepared from 4-methylpiperazine and 5-(5-bromoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Preparation 11), following the procedure of Example 1, and was obtained as a white solid (27%), m.p. 124-125°C. Found: C, 63.96; H, 7.19; N, 17.80. $C_{25}H_{34}N_6O_3$ requires C, 64.36; H, 7.34; N, 18.01%.

EXAMPLE 16

5-[5-(1-Hydroxy-2-morpholinoethyl)-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

This compound was prepared from 1-methyl-5-(5-morpholinoacetyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, following the procedure of Example 9, and was obtained as a white solid (28%), m.p. 104-105°C. Found: C, 62.90; H, 7.50; N, 15.48. $C_{24}H_{33}N_5O_4$ requires C, 63.28; H, 7.30; N, 15.37%.

EXAMPLE 17

5-(5-Acetyl-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

The title compound was prepared from 4-(5-acetyl-2-ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide (Preparation 15), following the procedure of Preparation 7, and was obtained as a white solid (77%), m.p. 196-198°C. Found: C, 64.35; H, 6.16; N, 15.85. $C_{18}H_{22}N_4O_3$ requires C, 64.39; H, 6.26; N, 15.81%.

EXAMPLE 18

5-(5-Bromo-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

N-Bromosuccinimide (2.6 g, 0.016 mol) in dimethylformamide (40 ml) was added dropwise to a stirred solution of 5-(2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Preparation 10, 4.0 g, 0.010 mol) in dimethylformamide (40 ml) at room temperature. After 7 hours the solvent was removed by evaporation under vacuum, the residue suspended in saturated aqueous sodium carbonate solution, and the resulting solution extracted with ethyl acetate (3 x 50 ml). The organic extracts were combined, dried (Na_2SO_4) and evaporated under vacuum. Trituration of the residue with ether, followed by crystallisation from ethyl acetate-hexane, gave the title compound as white crystals (3.39 g, 68%), m.p. 117-118°C. Found: C, 53.15; H, 5.03; N, 13.78. $C_{18}H_{21}BrN_4O_2$ requires C, 53.34; H, 5.22; N, 13.82%.

EXAMPLE 19

(E)-3-(1-Methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-n-propoxycinnamic acid t-butyl ester

To a solution of 5-(5-bromo-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (1.0 g, 0.0025 mol) and triethylamine (0.38 g, 0.0038 mol) in acetonitrile (2 ml), was added palla-

dium(II) acetate (0.03 g, 0.00013 mol), tri-*o*-tolylphosphine (0.076 g, 0.00025 mol) and *t*-butyl acrylate (0.48 g, 0.0038 mol). The mixture was heated under reflux for 4 hours, then cooled and evaporated under vacuum. The residue was suspended in water (30 ml) and extraction with dichloromethane (3 x 20 ml) effected. The organic extracts were combined, dried (Na₂SO₄) and evaporated under vacuum to give a yellow-green solid. Chromatography on silica gel (12 g), using a methanol in dichloromethane elution gradient (0-2% methanol), followed by crystallisation from ethyl acetate-hexane gave the title compound as a white solid (0.65 g, 58%), m.p. 167-168°C. Found: C, 66.47; H, 7.00; N, 12.31. C₂₅H₃₂N₄O₄ requires C, 66.35; H, 7.13; N, 12.38%.

EXAMPLE 20

(E)-3-(1-Methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-n-propoxycinnamic acid

2N Aqueous sodium hydroxide solution (2.28 ml, 0.0046 mol) was added to a solution of (E)-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-n-propoxycinnamic acid *t*-butyl ester (0.40 g, 0.00088 mol) in methanol (2.3 ml) and the mixture was heated under reflux for 18 hours. The methanol was removed by evaporation under vacuum, the residue dissolved in water (25 ml), and the solution extracted with ethyl acetate (4 x 15 ml). The aqueous layer was separated, acidified to pH 1 with hydrochloric acid, and then extracted with a mixture of methanol and ethyl acetate (3:97, 4 x 20 ml). The organic extracts were combined, dried (Na₂SO₄) and evaporated under vacuum, then the residue crystallised from ethyl acetate to give the title compound as a white solid (0.27 g, 77%), m.p. 229-230°C. Found: C, 63.64; H, 5.98; N, 14.14. C₂₁H₂₅N₄O₄ requires C, 63.46; H, 6.34; N, 14.10%.

EXAMPLE 21

5-(5(Bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Bromine (0.93 g, 0.0058 mol) was added dropwise to a stirred solution of 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Preparation 7, 1.1 g, 0.00352 mol) in glacial acetic acid (20 ml). The mixture was stirred at 100°C for 6.5 hours and the solvent was then removed by evaporation under vacuum. The residue was dissolved in a 9:1 mixture of methanol in dichloromethane (50 ml), and the solution washed with saturated aqueous sodium bicarbonate solution (50 ml), water (50 ml) and saturated brine (50 ml), then dried (MgSO₄) and evaporated under vacuum. The residue was chromatographed on silica gel (15 g) eluting with a mixture of methanol and dichloromethane (1:99) to give, after crystallisation from acetonitrile, the title compound (0.62 g, 45%), m.p. 157-159°C. Found: C, 52.41; H, 5.25; N, 14.01. C₁₇H₁₉BrN₄O₂ requires C, 52.18; H, 4.89; N, 14.32%.

EXAMPLE 22

(E)-4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)cinnamic acid *t*-butyl ester

The title compound was prepared from 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 19 and was obtained as a white crystalline solid (31%), m.p. 179-180°C. Found: C, 65.83; H, 6.90; N, 12.75. C₂₄H₃₀N₄O₄ requires C, 65.89; H, 6.68; N, 12.81%.

EXAMPLE 23

(E)-4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)cinnamic acid

The title compound was prepared from (E)-4-ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)cinnamic acid *t*-butyl ester following the procedure of Example 20 and was obtained as white crystals (66%), m.p. 234-236°C. Found: C, 63.01; H, 5.59; N, 14.62. C₂₀H₂₂N₄O₄ requires C, 62.82; H, 5.80; N, 14.65%.

EXAMPLE 24

3-[4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]propanoic acid

A solution of (E)-4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)cinnamic acid (0.426 g, 0.0011 mol) in a mixture of methanol (28.5 ml), ethyl acetate (100 ml) and water (1.5 ml), was stirred with 5% palladium on charcoal catalyst (0.05 g) under a hydrogen atmosphere at room temperature and pressure for 3 hours. The catalyst was removed by filtration and the solvent removed by evaporation under vacuum. Crystallisation of the residue from ethyl acetate-hexane gave the title compound as beige crystals (0.23 g, 54%), m.p. 165-167°C. Found: C,62.24; H,6.17; N,14.09. $C_{20}H_{24}N_4O_4$ requires C,62.39; H,6.33; N,14.41%.

EXAMPLE 25

(E)-4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-5-yl)cinnamic acid dimethylamide

The title compound was prepared from N,N-dimethylacrylamide and 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one following the procedure of Example 19 and was obtained, following crystallisation from ethyl acetate-hexane, as colourless crystals (38%), m.p. 219-221°C. Found: C,64.15; H,6.46; N,16.96. $C_{22}H_{27}N_5O_3$ requires C,64.53; H,6.65; N,17.10%.

EXAMPLE 26

3-[4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]propanoic acid dimethylamide

The title compound was prepared from (E)-4-ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)cinnamic acid dimethylamide following the procedure of Example 24 and, after crystallisation from ethyl acetate-hexane, was obtained as colourless crystals (74%), m.p. 155-157°C. Found: C,64.09; H,7.04; N,16.71. $C_{22}H_{29}N_5O_3$ requires C,64.21; H,7.10; N,17.02%.

EXAMPLE 27

(E)-4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo-4,3-d]pyrimidin-5-yl)cinnamionitrile

The title compound was prepared from acrylonitrile and 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-one following the procedure of Example 19 and was obtained as off-white crystals (33%). Found: C,65.99; H,5.52; N,19.07. $C_{20}H_{21}N_5O_2$ requires C,66.10; H,5.82; N,19.27%.

EXAMPLE 28

5-[5-(3-Aminopropyl)-2-ethoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A solution of (E)-4-ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)cinnamionitrile (0.25 g, 0.00064 mol) in glacial acetic acid (25 ml) was stirred with Raney nickel catalyst (25 mg) under hydrogen at room temperature and at 50 p.s.i. for 3 hours. The resulting mixture was filtered and the filtrate evaporated under vacuum. The residue was partitioned between saturated aqueous sodium carbonate solution (50 ml) and dichloromethane (30 ml), the layers separated and the aqueous phase further extracted with dichloromethane (2 x 30 ml). The organic solutions were combined, dried (Na_2SO_4) and evaporated under vacuum to give a brown solid, crystallisation of which from hexane-ethyl acetate gave the title compound as fawn crystals (96 mg, 38%), m.p. 115-117°C. Found C,65.29; H,7.35; N,18.66. $C_{20}H_{27}N_5O_2$ requires C,65.02; H,7.37; N,18.96%.

EXAMPLE 29

4-Ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)benzoic acid

- 5 n-Butyllithium (2.5 M solution in hexane, 1.53 ml, 0.0038 mol) was added dropwise to a stirred solution of 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.60 g, 0.00074 mol) in dry tetrahydrofuran (25 ml) at -78°C under a dry nitrogen atmosphere. After 0.3 hour at -78°C, the solution was allowed to warm to -40°C and carbon dioxide gas was bubbled through the solution. The resulting solution was allowed to warm to room temperature and then poured into water; acidification to pH 3 with 2N hydrochloric acid and extraction with a 9:1 mixture of dichloromethane and methanol (4 x 50 ml) were then effected. The organic extracts were combined, dried (MgSO₄) and evaporated under vacuum to give a colourless solid. Chromatography of this solid on silica gel (20 g), using a methanol in dichloromethane elution gradient (2-5% methanol), gave a solid which was dissolved in a 9:1 mixture of dichloromethane and methanol (50 ml); this solution was then washed with saturated aqueous sodium carbonate solution (50 ml), dried (MgSO₄) and evaporated under vacuum to give the title compound as a white powder (0.144 g, 26%), m.p. 285-288°C. Found: C, 60.74; H, 5.72; N, 15.61. C₁₈H₂₀N₄O₄ requires C, 60.66; H, 5.66; N, 15.72%.

EXAMPLE 30

- 20 5-[2-Ethoxy-5-(4-methylpiperazinylcarbonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

- A solution of 4-ethoxy-3-(1-methyl-7-oxo-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-5-yl)benzoic acid (0.095 g, 0.00027 mol), 1-methylpiperazine (0.265 g, 0.00265 mol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.077 g, 0.0004 mol) and 1-hydroxybenzotriazole (0.054 g, 0.0004 mol) in dichloromethane (25 ml) was stirred at room temperature for 18 hours. The reaction solution was washed with water (25 ml), dried (MgSO₄) and evaporated under vacuum, and then the resulting residue crystallised from ethyl acetate-hexane to give the title compound as colourless crystals (0.03 g, 25%), m.p. 196-197°C. Found: C, 63.12; H, 6.81; N, 18.96. C₂₃H₃₀N₆O₃ requires C, 62.99; H, 6.90; N, 19.16%.

EXAMPLE 31

5-[2-Ethoxy-5-(1-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

- 35 A solution of 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.20 g, 0.00051 mol), imidazole (0.172 g, 0.0025 mol), anhydrous potassium carbonate (0.077 g, 0.00056 mol), copper bronze (0.036 g, 0.00057 mol) and iodine (0.015 g, 0.00012 mol) in dimethylformamide (10 ml) was heated under reflux under nitrogen for 4.5 hours, cooled and poured into water (50 ml). This mixture was extracted with a 9:1 mixture of dichloromethane and methanol (6 x 50 ml) and the extracts combined, dried (MgSO₄) and evaporated under vacuum to give a pale brown oil. The oil was chromatographed on silica gel (20 g), eluting with a mixture of dichloromethane, methanol and triethylamine (97.8:2:0.2), to give a yellow solid, crystallisation of which from ethyl acetate-hexane gave the title compound as a cream solid (0.073 g, 38%), m.p. 193-194°C. Found: C, 63.61; H, 5.97; N, 22.03. C₂₀H₂₂N₆O₂ requires C, 63.48; H, 5.86; N, 22.21%.

EXAMPLE 32

5-[2-Ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

- 50 n-Butyllithium (1.6 M solution in hexane, 9.6 ml, 0.0153 mol) was added to a stirred solution of 1-methylimidazole (0.628 g, 0.0077 mol) in dry tetrahydrofuran (10 ml) at -78°C, and the resulting solution stirred for 0.25 hours. A solution of anhydrous zinc chloride (2.08 g, 0.0153 mol) in dry tetrahydrofuran (15 ml) was added, the mixture allowed to warm to room temperature, then 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (1.0 g, 0.0026 mol) and tetrakis(triphenylphosphine)palladium(0) (0.036 g, 0.031 mol) were added and the mixture heated under reflux for 18 hours. A further quantity of anhydrous zinc chloride (2.08 g, 0.0153 mol) was added and the resulting mixture heated under reflux for a further 60 hours, then cooled; methanol (2 ml) was added and the solvent removed by evaporation under vacuum. The residue was heated with a solution of disodium ethylenediaminetetraacetic acid dihydrate (23.0 g, 0.0618

mol) in water (100 ml) to 100°C for 0.2 hour, then the resulting solution basified to pH 8 with saturated aqueous sodium carbonate solution and extracted with dichloromethane (6 x 100 ml). The organic extracts were combined, dried (Na₂SO₄) and evaporated under vacuum to give a yellow solid, purification of which by chromatography on silica gel (13 g), using a methanol-dichloromethane elution gradient (0-3% methanol), followed by crystallisation from ethyl acetate, gave the title compound as an off-white solid (0.542 g, 53%), m.p. 199-202°C. Found: C,64.45; H,6.27; N,21.56. C₂₁H₂₄N₆O₂ requires C,64.27; H,6.16; N,21.42%.

EXAMPLE 33

5-[2-Ethoxy-5-(2-pyridyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

The title compound was prepared from 2-bromopyridine and 5-(5-bromo-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, following the procedure described in Example 32, and was obtained as an off-white solid (33%), m.p. 216-218°C. Found: C,67.61; H,5.81; N,17.63. C₂₂H₂₃N₅O₂ requires C,67.85; H,5.95; N,17.98%.

EXAMPLE 34

1-Methyl-5-(5-morpholinomethyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo-[4,3-d]pyrimidin-7-one

A solution of 5-(5-chloromethyl-2-n-propoxymethyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Preparation 16, 0.60 g, 0.0016 mol) in 2-butanone (10 ml) was added dropwise to a stirred solution of morpholine (0.42 g, 0.0048 mol) in 2-butanone (40 ml) at 0°C. The solution was then heated under reflux for 16 hours, cooled and evaporated under vacuum. The residue was suspended in water (50 ml) and the suspension extracted with ethyl acetate (3 x 20 ml). The organic extracts were combined, washed with brine (2 x 30 ml), dried (Na₂SO₄) and evaporated under vacuum. The residue was chromatographed on silica gel (12 g), using an elution gradient of methanol in dichloromethane (0-2% methanol), to give an oil which solidified on trituration with hexane. Crystallisation from ethyl acetate-hexane gave the title compound as a colourless solid (0.36 g, 53%), m.p. 106-107°C. Found: C,64.76; H,7.34; N,16.36. C₂₃H₃₁N₅O₃ requires C,64.92; H,7.34; N,16.46%.

EXAMPLE 35

1-Methyl-5-[5-(4-methyl-1-piperazinylmethyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

The title compound was prepared from 5-(5-chloromethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and 1-methylpiperazine, following the procedure of Example 34, and was obtained as a colourless solid (36%), m.p. 149-150°C. Found: C,65.68; H,7.83; N,19.10. C₂₄H₃₄N₆O₂ requires C,65.73; H,7.81; N,19.16%.

EXAMPLE 36

1-Methyl-5-(5-methyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A solution of 5-(5-chloromethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.5 g, 0.0013 mol) in ethyl acetate (50 ml) was stirred with 10% palladium on charcoal catalyst under a hydrogen atmosphere at 50 p.s.i. and room temperature. After 1 hour, the mixture was filtered and the filtrate evaporated under vacuum to give a pale green solid. Chromatography on silica gel (4 g) using a methanol in dichloromethane elution gradient gave a white solid, crystallisation of which from hexane-ethyl acetate gave the title compound as colourless needles (0.12 g, 26%), m.p. 115-116°C. Found: C,66.66; H,7.12; N,16.55. C₁₉H₂₄N₄O₂ requires C,67.04; H,7.11; N,16.46%.

EXAMPLE 375-(5-Hydroxymethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 To a solution of 5-(5-chloromethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.5 g, 0.0013 mol) in dimethyl sulphoxide (10 ml) was added sodium hydroxide (0.26 g, 0.0065 mol) and ethylene glycol (0.41 g, 0.0065 mol). The reaction mixture was heated at 100°C for 6 hours, allowed to cool and poured into water (50 ml), then the aqueous mixture extracted with ethyl acetate (3 x 30 ml). The combined extracts were filtered, dried (Na₂SO₄) and evaporated under vacuum to provide an oil which
 10 was purified by chromatography on silica gel (6 g), using a methanol in dichloromethane elution gradient (0-3% methanol). The solid product was crystallised from hexane-ethyl acetate to afford the title compound as a white solid (2%), m.p. 174-175°C. Found: C,63.97; H,6.66; N,15.57. C₁₉H₂₄N₄O₃ requires C,64.03; H,6.79; N,15.72%.

EXAMPLE 385-(5-Ethoxymethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Sodium (0.15 g, 0.0013 mol) was added portionwise to ethanol (40 ml) over 1 hour. 5-(5-Chloromethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.5 g, 0.0013 mol)
 20 was then added to the solution and, after 3 days at room temperature, the solvent was removed by evaporation under vacuum. The residual solid was suspended in water (50 ml) and the suspension extracted with ethyl acetate (3 x 30 ml). The extracts were then combined, dried (Na₂SO₄) and evaporated under vacuum to give a green solid. Chromatography on silica gel (6 g) using a methanol in dichloromethane elution gradient gave, after crystallisation of the required product from a hexane-ethyl acetate mixture, the title compound as a white solid (0.2
 25 g, 39%) m.p. 89-90°C. Found: C,65.87; H,7.57; N,14.66. C₂₁H₂₈N₄O₃ requires C,65.60; H,7.34; N,14.57%.

EXAMPLE 395-[5-(2-Hydroxyethoxymethyl)-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

This compound was prepared from 5-(5-chloromethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and ethylene glycol following the procedure of Example 38 and was obtained as a white solid (45%), m.p. 101-102°C. Found: C,63.13; H,6.88; N,13.98. C₂₁H₂₈N₄O₄ requires C,62.98; H,7.05; N,13.99%.

EXAMPLE 401-Methyl-5-[5-(2-morpholinoethoxymethyl)-2-n-propoxyphenyl]-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

(a) Methanesulphonyl chloride (0.56 g, 0.0049 mol) was added to a stirred solution of 5-[5-(2-hydroxyethoxymethyl)-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
 45 (1.8 g, 0.0045 mol) in pyridine (25 ml) at 0°C. After 18 hours at room temperature, the solvent was removed by evaporation under vacuum and the residue partitioned between 2N hydrochloric acid (30 ml) and dichloromethane (30 ml). The aqueous layer was separated and extracted with dichloromethane (2 x 30 ml), then the organic solutions combined, dried (Na₂SO₄) and evaporated under vacuum to give a brown oil. Chromatography on silica gel (12 g) using a methanol in dichloromethane elution gradient (0-3% methanol)
 50 gave an oil, titration of which with hexane, followed by crystallisation from hexane-ethyl acetate, gave the required mesylate as white crystals (0.19 g, 9%), m.p. 74-76°C. Found: C,55.71; H,6.25; N,11.69. C₂₂H₃₀N₄O₆S requires C,55.21; H,6.32; N,11.71%.

(b) Morpholine (0.19 g, 0.0021 mol) was added to a solution of the above mesylate, namely 5-[5-(2-methanesulphonyloxyethoxymethyl)-2-n-propoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, (0.20 g, 0.00042 mol) in acetonitrile (25 ml) and the stirred mixture was heated under reflux for 18 hours. The solvent was removed by evaporation under vacuum, the residue dissolved in saturated aqueous sodium carbonate solution and the solution extracted with ethyl acetate (3 x 20 ml). The extracts were combined, dried (Na₂SO₄) and evaporated under vacuum, and the residue was chromato-

graphed on silica gel (4 g) using an elution gradient of methanol in dichloromethane (0-2% methanol). Evaporation under vacuum of the appropriate fractions, followed by crystallisation from hexane, gave the title compound as white crystals (0.098 g, 48%), m.p. 65-66°C. Found: C, 64.17; H, 7.69; N, 14.96. $C_{25}H_{35}N_5O_5$ requires C, 63.94; H, 7.51; N, 14.91%.

EXAMPLE 41

5-(2-Ethoxy-5-methanesulphonamidophenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Methanesulphonyl chloride (0.157 g, 0.00137 mol) was added to a stirred solution of 5-(5-amino-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.45 g, 0.00137 mol) in dry pyridine (30 ml) at 0°C. The mixture was stirred for 18 hours at room temperature and then evaporated under vacuum. The residue was suspended in saturated aqueous sodium bicarbonate solution (50 ml) and the mixture extracted with dichloromethane (2 x 30 ml). The organic extracts were combined, washed with brine (2 x 30 ml), dried (Na_2SO_4) and evaporated under vacuum. The residue was triturated with ether, chromatographed on silica gel (12 g), eluting with a 98.5:1.5 mixture of dichloromethane and methanol, and the required product crystallised from ethyl acetate-hexane to give the title compound as a white powder (0.32 g, 58%), m.p. 205-206°C. Found: C, 53.63; H, 5.66; N, 17.24. $C_{18}H_{23}N_5O_4S$ requires C, 53.32; H, 5.72; N, 17.27%.

EXAMPLE 42

5-[2-Ethoxy-5-(3-morpholinopropylsulphonamido)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

The title compound was prepared from 5-(5-amino-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one and 3-morpholinopropylsulphonyl chloride, following the procedure of Example 41, and was obtained as brown crystals (14%), m.p. 157-159°C. Found: C, 55.42; H, 6.53; N, 16.01. $C_{24}H_{34}N_6O_5S$ requires C, 55.58; H, 6.61; N, 16.21%.

EXAMPLE 43

5-[2-Ethoxy-5-(4-methyl-1-piperazinyl)sulphonamidophenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

The title compound was prepared from 4-methyl-1-piperazinylsulphonyl chloride and 5-(5-amino-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, following the procedure of Example 41, and was obtained as an orange powder (13%), m.p. 152-153°C. Found: C, 54.32; H, 6.38; N, 19.88. $C_{22}H_{31}N_7O_4S$ requires C, 53.97; H, 6.38; N, 20.03%.

EXAMPLE 44

5-[5-(4-Benzyl-1-piperazinylsulphonamidophenyl)-2-ethoxy]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

4-Benzyl-1-piperazinylsulphonyl chloride (Preparation 19, 0.9 g, 0.0029 mol) was added to a stirred solution of 5-(5-amino-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.94 g, 0.0029 mol), 4-dimethylaminopyridine (0.050 g, 0.00041 mol) and triethylamine (1.09 g, 0.0108 mol) in dichloromethane (50 ml). The solution was stirred at room temperature for 48 hours and then evaporated under vacuum. The residue was suspended in saturated aqueous sodium bicarbonate solution (50 ml) and the suspension extracted with dichloromethane (3 x 30 ml). The organic extracts were combined, washed successively with saturated aqueous sodium bicarbonate solution (2 x 20 ml) and brine (3 x 20 ml), dried (Na_2SO_4) and evaporated under vacuum. The residue was chromatographed on silica gel (20 g) using a methanol in dichloromethane elution gradient (0-4% methanol), and the required product crystallised from ethyl acetate-hexane to give the title compound as an off-white powder (0.185 g, 11%). Found: C, 58.30; H, 6.20; N, 16.80. $C_{28}H_{35}N_7O_4S$; 0.5H₂O requires C, 58.52; H, 6.31; N, 17.06%.

PREPARATION 1**1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester**

5 A mixture of 3-n-propylpyrazole-5-carboxylic acid ethyl ester (24.1 g, 0.132 mol) (prepared by the method of Chem. Pharm. Bull., 1984, 32, 1568) and dimethyl sulphate (16.8 g, 0.133 mol) were heated to 90°C for 2.5 hours. The mixture was dissolved in dichloromethane and the solution washed with aqueous sodium carbonate solution. The organic phase was separated, dried (MgSO₄) and evaporated under vacuum to give a solid. Chromatography on silica gel (300 g), eluting with dichloromethane, gave the product as a colourless oil (20.4 g, 79%). R_f 0.8 (silica, dichloromethane, methanol, acetic acid; 80:20:1).

PREPARATION 2**1-Methyl-3-n-propylpyrazole-5-carboxylic acid**

15 1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester (20.2 g, 0.10 mol) was suspended in 6N aqueous sodium hydroxide solution (50 ml, 0.30 mol). The mixture was heated to 80°C for 2 hours then diluted with water (50 ml) and acidified with concentrated hydrochloric acid (25 ml). Filtration gave the carboxylic acid as pale brown crystals (12.3 g, 71%), m.p. 150-154°C. Found: C,56.99; H,7.25; N,16.90. C₈H₁₂N₂O₂ requires C,57.13; H,7.19; N,16.66%.

PREPARATION 3**1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid**

25 1-Methyl-3-n-propylpyrazole-5-carboxylic acid (12.1 g, 0.072 mol) was added portionwise to a mixture of oleum (13 ml) and fuming nitric acid (11 ml), keeping the temperature below 60°C. After the addition, the mixture was heated at 60°C overnight, and then cooled to room temperature before being poured onto ice; filtration then gave the nitropyrazole as a white solid (11.5 g, 75%), m.p. 124-127°C. Found: C,45.43; N,5.22; N,19.42. C₈H₁₁N₃O₄ requires C,45.57; H,5.20; N,19.71%.

PREPARATION 4**1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxamide**

35 1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid (11.3 g, 0.053 mol) was added to thionyl chloride (50 ml) and the resulting mixture heated under reflux for 3 hours. The reaction mixture was then cooled and excess thionyl chloride removed by evaporation under vacuum. The oily residue was dissolved in acetone (50 ml) and the solution cautiously added to a mixture of ice (50 g) and concentrated aqueous ammonium hydroxide solution (50 ml). The precipitate was collected by filtration to provide the pyrazolecarboxamide as a pale yellow solid (8.77 g, 78%), m.p. 141-143°C. Found: C,45.22; H,5.71; N,26.12. C₈H₁₂N₄O₃ requires C,45.28; H,5.70; N,26.40%.

PREPARATION 5**4-Amino-1-methyl-3-n-propylpyrazole-5-carboxamide**

45 1-Methyl-4-nitro-3-n-propylpyrazole-5-carboxamide (3.45 g, 16.2 mmol) and stannous chloride dihydrate (18.4 g, 81 mmol) were suspended in ethanol and the mixture heated under reflux for 2 hours. The resulting solution was cooled to room temperature, basified to pH 9 by the addition of 2N aqueous sodium hydroxide solution and extracted with dichloromethane (3 x 150 ml). The organic extracts were combined, dried (MgSO₄) and evaporated under vacuum. Trituration of the residue with ether gave the aminopyrazole as an off-white solid (2.77 g, 94%), m.p. 98-101°C. Found: C,52.84; H,7.81; N,30.38. C₈H₁₄N₄O requires C,52.73; H,7.74; N,30.75%.

PREPARATION 6**4-(2-Ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide**

A solution of 2-ethoxybenzoyl chloride (6.1 g, 33.0 mmol) in dichloromethane (50 ml) was added to a stirred solution of 4-amino-1-methyl-3-n-propylpyrazole-5-carboxamide (3.0 g, 16.4 mmol), 4-dimethylaminopyridine (0.02 g, 0.164 mmol) and triethylamine (3.34 g, 33.0 mmol) in dichloromethane (50 ml) at 0°C. The resulting mixture was allowed to warm to room temperature and stirred for a further 2 hours. The solvent was evaporated under vacuum, the residue dissolved in a 19:1 mixture of dichloromethane and methanol (250 ml), and then the solution washed with 1N hydrochloric acid (100 ml), dried (MgSO₄) and evaporated under vacuum. The crude material was chromatographed on silica gel (200 g), eluting with a 97:3 mixture of dichloromethane and methanol, to give a pink solid; crystallisation from ethyl acetate-hexane gave the pyrazole-5-carboxamide as a pale pink solid (2.2 g, 40%), m.p. 153-155°C. Found: C, 61.66; H, 6.77; N, 16.95. C₁₇H₂₂N₄O₃ requires C, 61.80; H, 6.71; N, 16.96%.

PREPARATION 7**5-(2-Ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one**

4-(2-Ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide (223 g, 0.676 mol) was added portionwise to a solution of sodium hydroxide (54 g, 1.35 mol) and 30% hydrogen peroxide solution (224 ml) in water (2000 ml). Ethanol (700 ml) was added and the resulting mixture heated under reflux for 2.5 hours, cooled, then evaporated under vacuum. The resulting solid was treated with 2N hydrochloric acid (380 ml), with external cooling, and the mixture was extracted with dichloromethane (1 x 700 ml, 3 x 200 ml). The combined organic extracts were washed successively with saturated aqueous sodium carbonate solution (3 x 400 ml) and brine (300 ml), then dried (Na₂SO₄) and evaporated under vacuum.

Chromatography of the residue on silica gel (1000 g), using a methanol in dichloromethane elution gradient (0-1% methanol), followed by trituration of the crude product with ether (300 ml), gave the title compound as a colourless solid (152.2 g, 72%), m.p. 143-146°C. Found: C, 65.56; H, 6.44; N, 18.14. C₁₇H₂₀N₄O₂ requires C, 65.36; H, 6.45; N, 17.94%.

PREPARATION 8**5-(5-Bromoacetyl-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one**

Aluminium trichloride (12.8 g, 0.096 mol) was added portionwise over 1 hour to a stirred solution of 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (10.0 g, 0.032 mol) and bromoacetyl bromide (5.6 ml, 0.064 mol) in dichloromethane (150 ml) at 0°C. After 18 hours at room temperature, the reaction mixture was poured into ice and water (400 g) and the resulting mixture stirred vigorously. The organic phase was separated and the aqueous phase further extracted with dichloromethane (2 x 100 ml). The organic solutions were combined, dried (Na₂SO₄) and evaporated under vacuum to give an off-white solid, trituration of which from ether gave the title compound as a white solid (10.87 g, 78%), m.p. 159-160°C. Found: C, 52.54; H, 4.88; N, 12.78. C₁₉H₂₁BrN₄O₃ requires C, 52.67; H, 4.88; N, 12.93%.

PREPARATION 9**1-Methyl-4-(2-n-propoxybenzamido)-3-n-propylpyrazole-5-carboxamide**

This amide was prepared from 2-n-propoxybenzoyl chloride following the procedure described in Preparation 6 and was obtained as a pink solid (63%), m.p. 148-149°C. Found: C, 62.97; H, 7.00; N, 16.29. C₁₈H₂₄N₄O₃ requires C, 62.77; H, 7.02; N, 16.27%.

PREPARATION 10**1-Methyl-5-(2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one**

1-Methyl-4-(2-n-propoxybenzamido)-3-n-propylpyrazole-5-carboxamide (0.34 g, 0.99 mmol) was added to a stirred mixture of 30% hydrogen peroxide solution (1.0 ml), potassium carbonate (0.54 g, 3.92 mmol), water

(10 ml) and ethanol (5 ml). The mixture was heated under reflux for 38 hours and then evaporated under vacuum. The residue was suspended in water (20 ml), then the suspension acidified with 2N hydrochloric acid and extracted with dichloromethane (3 x 20 ml). The extracts were combined, dried (Na_2SO_4) and evaporated under vacuum. The resulting residue was chromatographed on silica gel (6 g), using a methanol in dichloromethane elution gradient (0-1% methanol), to give an oil, successive trituration of which with ether gave the required product as a white solid (0.19 g, 59%), m.p. 111-114°C. Found: C,66.26; H,6.92; N,17.15. $\text{C}_{18}\text{H}_{22}\text{N}_4\text{O}_2$ requires C,66.23; H,6.80; N,17.17%.

PREPARATION 11

5-(5-Bromoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Aluminium trichloride (6.0 g, 0.045 mol) was added portionwise to a stirred solution of 1-methyl-5-(2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (5.0 g, 0.0153 mol) and 2-bromoacetyl chloride (2.5 ml, 0.0303 mol) in dichloromethane (100 ml) at 0°C. The reaction mixture was allowed to warm to room temperature, stirred for 18 hours, heated under reflux for 3 hours and then added cautiously to ice and water (100 g). The resulting mixture was stirred for 1 hour and extracted with dichloromethane (2 x 50 ml). The combined organic extracts were washed with brine (2 x 50 ml), dried (Na_2SO_4), then evaporated under vacuum to give an off-white solid, which was triturated with ether to give the title compound as a white solid (4.1 g, 60%). A small sample was crystallised from ethyl acetate:hexane to give the pure product, m.p. 136-137°C. Found: C,53.82; H,5.24; N,12.57. $\text{C}_{20}\text{H}_{23}\text{BrN}_4\text{O}_3$ requires C,53.70; H,5.18; N,12.52%.

PREPARATION 12

5-Acetyl-2-ethoxybenzoic acid methyl ester

Iodoethane (16.4 g, 0.105 mol) was added to a stirred mixture of 5-acetyl-2-hydroxybenzoic acid methyl ester (10 g, 51.5 mol) and anhydrous potassium carbonate (14.4 g, 0.104 mol) in 2-butanone (200 ml) and the resulting mixture heated under reflux for 3 days. The solvent was removed by evaporation under vacuum and the residue partitioned between water (100 ml) and ethyl acetate (100 ml). The aqueous phase was removed and extracted with further ethyl acetate (4 x 100 ml). The organic solutions were combined, dried (Na_2SO_4) and evaporated under vacuum. The residue was chromatographed on silica gel (130 g), using a methanol in dichloromethane elution gradient (0-1% methanol), to give the title compound as colourless crystals (10.15 g, 89%), m.p. 50-55°C. Found: C,64.88; H,6.38. $\text{C}_{12}\text{H}_{14}\text{O}_4$ requires C,64.85; H,6.35%.

PREPARATION 13

5-Acetyl-2-ethoxybenzoic acid

A mixture of 5-acetyl-2-ethoxybenzoic acid methyl ester (9.6 g, 0.043 mol), 5M aqueous sodium hydroxide solution (44 ml, 0.217 mol), water (80 ml) and 1,4-dioxan (80 ml) was stirred at room temperature for 18 hours. The solvent was removed by evaporation under vacuum, the residue dissolved in water (100 ml) and the resulting solution acidified to pH 1 with concentrated hydrochloric acid. The aqueous mixture was extracted with ethyl acetate (4 x 100 ml) and the combined extracts dried (Na_2SO_4) and evaporated under vacuum. The resulting solid was crystallised from ethyl acetate to give the title compound as a colourless solid (5.4 g, 60%), m.p. 122-125°C. Found: C,63.20; H,5.81. $\text{C}_{11}\text{H}_{12}\text{O}_4$ requires C,63.45; H,5.81%.

PREPARATION 14

5-Acetyl-2-ethoxybenzoyl chloride

Oxalyl chloride (3.66 g, 0.029 mol) was added dropwise to a stirred solution of 5-acetyl-2-ethoxybenzoic acid (3.0 g, 0.014 mol) in dichloromethane (15 ml) and dimethylformamide (0.1 ml). After 3 hours at room temperature, the solvent was removed by evaporation under vacuum and the residue azeotroped with hexane (3 x 30 ml) to give the title compound, which was used without further purification.

PREPARATION 154-(5-Acetyl-2-ethoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide

The title compound was prepared from 5-acetyl-2-ethoxybenzoyl chloride and 4-amino-1-methyl-3-n-propylpyrazole-5-carboxamide following the procedure of Preparation 6, and was obtained as a white solid (60%), m.p. 225-227°C. Found: C,61.35; H,6.25; N,15.07. $C_{19}H_{24}N_4O_4$ requires C,61.28; H,6.50; N,15.04%.

PREPARATION 165-(5-Chloromethyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

1-Methyl-5-(2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.80 g, 0.00246 mol) was added portionwise to stirred concentrated hydrochloric acid (10 ml) at room temperature. Paraformaldehyde (0.20 g, 0.00246 mol) was then added and the resulting solution stirred at 120°C for 22 hours. The reaction mixture was cooled and poured into ice and water (50 g), then the resulting mixture extracted with ethyl acetate (3 x 30 ml). The organic extracts were combined, dried (Na_2SO_4) and evaporated under vacuum to give a white solid. Trituration with ether, followed by crystallisation from ethyl acetate-hexane, gave the title compound as colourless crystals (0.65 g, 70%), m.p. 102-104°C. Found: C,60.91; H,6.14; N,14.94. $C_{19}H_{23}ClN_4O_2$ requires C,60.88; H,6.18; N,14.95%.

PREPARATION 175-(2-Ethoxy-5-nitrophenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Concentrated nitric acid (0.5 ml) was added dropwise to a stirred solution of 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (2.0 g, 0.0064 mol) in concentrated sulphuric acid (10 ml) at 0°C, and the resulting orange solution was stirred at room temperature for 18 hours. The reaction solution was then added dropwise to stirred ice and water (200 g) and the solid precipitate collected by filtration. This solid was then dissolved in dichloromethane (50 ml) and the solution washed successively with brine (2 x 30 ml) and water (30 ml), dried (Na_2SO_4) and evaporated under vacuum to give a yellow solid. Crystallisation from acetonitrile gave the title compound as yellow needles (1.40 g, 61%), m.p. 214-216°C. Found: C,57.36; H,5.21; N,19.49. $C_{17}H_{19}N_5O_4$ requires C,57.13; H,5.36; N,19.60%.

PREPARATION 185-(5-Amino-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5-(2-Ethoxy-5-nitrophenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (0.64 g, 0.0018 mol) was dissolved in ethanol (50 ml) and the solution stirred with 5% palladium on charcoal catalyst (0.050 g) under hydrogen at room temperature and 50 p.s.i. pressure for 4 hours. The mixture was filtered to remove the catalyst, the filtrate evaporated under vacuum, and the residue triturated with ether to give the title compound as an off-white solid (0.56 g, 95%), m.p. 147-148°C. Found: C,62.63; H,6.60; N,21.57. $C_{17}H_{21}N_5O_2$ requires C,62.36; H,6.47; N,21.39%.

PREPARATION 194-Benzyl-1-piperazinylsulphonyl chloride

A solution of 1-benzylpiperazine (20.0 g, 0.114 mol) in acetonitrile (45 ml) was added to a solution of sulphonyl chloride (28 ml, 0.346 mol) in acetonitrile (50 ml) and the mixture heated under reflux for 17 hours, then cooled. The solvent was removed by evaporation under vacuum, then the residue triturated with ether (20 x 50 ml) to yield the title compound (27.8 g, 89%), which was used without further purification.

Biological activity

The following Table illustrates the *in vitro* activities for a range of the compounds of the invention.

TABLE

IN VITRO PDE INHIBITORY DATA:

SELECTIVITY BETWEEN CALCIUM/CALMODULIN (Ca/CAM) -
INDEPENDENT cGMP PDE AND cGMP-INHIBITED cAMP PDE


EXAMPLE	IC ₅₀ (nM)		SELECTIVITY RATIO
	cGMP	cAMP	
3	2.2	86,000	39,090
4	1.8	63,000	35,000
11	4.9	57,000	11,632
14	1.0	57,000	57,000
15	3.4	75,000	22,058
16	3.7	53,000	14,324
20	3.7	59,000	15,945
25	3.4	84,000	24,705
29	5.5	84,000	15,272
30	1.4	58,000	41,428
31	3.4	56,000	16,470
32	1.4	38,000	27,142
39	5.3	54,000	10,188

Safety profile

Certain compounds of the invention have been tested at therapeutic doses of up to 1 mg/Kg i.v. and up to 3 mg/Kg p.o. in rats with no signs of adverse acute toxicity being observed. In mice, no deaths occurred after doses of up to 100 mg/Kg i.v.

Claims

1. A compound of formula:



or a pharmaceutically acceptable salt thereof,
wherein

R¹ is H; C₁-C₃ alkyl optionally substituted with one or more fluoro substituents; or C₃-C₅ cycloalkyl;

R² is H, or C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl;

R³ is C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl; C₃-C₅ cycloalkyl; C₃-C₆ alkenyl; or C₃-C₆ alkynyl;

R⁴ is C₁-C₄ alkyl optionally substituted with OH, NR⁵R⁶, CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkenyl optionally substituted with CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkanoyl optionally substituted with NR⁵R⁶; hydroxy C₂-C₄ alkyl optionally substituted with NR⁵R⁶; (C₂-C₃ alkoxy)C₁-C₂ alkyl optionally substituted with OH or NR⁵R⁶; CONR⁵R⁶; CO₂R⁷; halo; NR⁵R⁶; NHSO₂NR⁵R⁶; NHSO₂R⁸; or phenyl or heterocyclyl either of which is optionally substituted with methyl;

R⁵ and R⁶ are each independently H or C₁-C₄ alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-(NR⁹)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy;

R⁷ is H or C₁-C₄ alkyl;

R⁸ is C₁-C₃ alkyl optionally substituted with NR⁵R⁶;

and

R⁹ is H; C₁-C₃ alkyl optionally substituted with phenyl; hydroxy C₂-C₃ alkyl; or C₁-C₄ alkanoyl.


2. A compound as claimed in claim 1 wherein R¹ is H, methyl or ethyl; R² is C₁-C₃ alkyl; R³ is C₂-C₃ alkyl; R⁴ is C₁-C₂ alkyl optionally substituted with OH, NR⁵R⁶, CONR⁵R⁶ or CO₂R⁷; acetyl optionally substituted with NR⁵R⁶; hydroxyethyl substituted with NR⁵R⁶; ethoxymethyl optionally substituted with OH or NR⁵R⁶; CH=CHCN; CH=CHCONR⁵R⁶; CH=CHCO₂R⁷; CO₂H; CONR⁵R⁶; Br; NR⁵R⁶; NHSO₂NR⁵R⁶; NHSO₂R⁸; or pyridyl or imidazolyl either of which is optionally substituted with methyl; R⁵ and R⁶ are each independently H, methyl or ethyl, or together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-(NR⁹)-1-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy; R⁷ is H or t-butyl; R⁸ is methyl or CH₂CH₂CH₂NR⁵R⁶; and R⁹ is H, methyl, benzyl, 2-hydroxyethyl or acetyl.
3. A compound as claimed in claim 2 wherein R¹ is methyl; R² is n-propyl; R³ is ethyl or n-propyl; R⁴ is CH₂NR⁵R⁶, CH₂OCH₂CH₂NR⁵R⁶, CH₂OCH₂CH₃, CH₂OCH₂CH₂OH, COCH₂NR⁵R⁶, CH(OH)CH₂NR⁵R⁶, CH=CHCON(CH₃)₂, CH=CHCO₂R⁷, CO₂H, CONR⁵R⁶, Br, NHSO₂NR⁵R⁶, NHSO₂CH₂CH₂CH₂NR⁵R⁶, 2-pyridyl, 1-imidazolyl or 1-methyl-2-imidazolyl; R⁵ and R⁶ together with the nitrogen atom to which they are attached form a piperidino, 4-hydroxypiperidino, morpholino, 4-(NR⁹)-1-piperazinyl or 2-methyl-1-imidazolyl group; R⁷ is H or t-butyl; and R⁹ is H, methyl, benzyl, 2-hydroxyethyl or acetyl.
4. A compound as claimed in claim 3 wherein the said compound is selected from:
 - 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
 - 5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
 - 5-[5-(4-acetyl-1-piperazinyl)acetyl-2-ethoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
 - 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
 - and 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,
 and pharmaceutically acceptable salts thereof.
5. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, together with a pharmaceutically acceptable diluent or carrier.
6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, as claimed in any one of claims 1 to 5, for use in medicine.
7. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, as claimed in any one of claims 1 to 5, for the manufacture of a med-

icament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

8. A method of treating or preventing stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility, in a mammal (including a human being), which comprises administering to said mammal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, as claimed in any one of claims 1 to 5.

Claims for the following Contracting States : ES, GR

1. A process for the preparation of a compound of formula:



or a pharmaceutically acceptable salt thereof,
wherein

R¹ is H; C₁-C₃ alkyl optionally substituted with one or more fluoro substituents; or C₃-C₆ cycloalkyl;
R² is H, or C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl;

R³ is C₁-C₆ alkyl optionally substituted with one or more fluoro substituents or with C₃-C₆ cycloalkyl;
C₃-C₅ cycloalkyl; C₃-C₆ alkenyl; or C₃-C₆ alkynyl;

R⁴ is C₁-C₄ alkyl optionally substituted with OH, NR⁵R⁶, CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkenyl optionally substituted with CN, CONR⁵R⁶ or CO₂R⁷; C₂-C₄ alkanoyl optionally substituted with NR⁵R⁶; hydroxy C₂-C₄ alkyl optionally substituted with NR⁵R⁶; (C₂-C₃ alkoxy)C₁-C₂ alkyl optionally substituted with OH or NR⁵R⁶; CONR⁵R⁶; CO₂R⁷; halo; NR⁵R⁶; NHSO₂NR⁵R⁶; NHSO₂R⁸; or phenyl or heterocyclyl either of which is optionally substituted with methyl;


R⁵ and R⁶ are each independently H or C₁-C₄ alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-(NR⁹)piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy;

R⁷ is H or C₁-C₄ alkyl;

R⁸ is C₁-C₃ alkyl optionally substituted with NR⁵R⁶;

and

R⁹ is H; C₁-C₃ alkyl optionally substituted with phenyl; hydroxy C₂-C₃ alkyl; or C₁-C₄ alkanoyl;
which comprises reacting a compound of formula (II):



wherein R¹, R² and R³ are as previously defined in this claim, for a compound of formula (I) when R⁴ is

(A) C₂-C₄ alkanoyl or hydroxy C₂-C₄ alkyl,

with an acyl halide of formula (C₁-C₃ alkyl)COY wherein Y is halo, in the presence of a Lewis acid, optionally followed by reduction of the resulting ketone to the corresponding alcohol;

(B) C₂-C₄ alkanoyl or hydroxy C₂-C₄ alkyl, each substituted with NR⁵R⁶ wherein R⁵ and R⁶ are as previously defined in this claim,

with a haloacyl halide of formula X(C₁-C₃ alkylene)COY wherein X is halo and Y is as previously defined in this claim, in the presence of a Lewis acid, followed by reaction of the resulting haloketone either with an amine of formula R⁵R⁶NH, optionally followed by reduction of the resulting aminoketone, or with a protected amine of formula R⁵NHP, R⁶NHP or P'₂NH wherein P and P' are suitable amine protecting groups, optionally followed by reduction of the resulting aminoketone before or after removal of P or P';

(C) C₁-C₄ alkyl optionally substituted with OH, NR⁵R⁶, CONR⁵R⁶ or CO₂R⁷ wherein R⁵, R⁶ and R⁷ are as previously defined in this claim, or bromo,

(i) under chloromethylation conditions, followed by subsection of the resulting chloromethyl intermediate to, respectively,

(a) reduction, or

(b) reaction with an alkali metal hydroxide, or

(c) reaction with an amine of formula R⁵R⁶NH, or

(d) reaction with an alkali metal cyanide and optionally converting the resulting nitrile to the corresponding amide, acid or ester; or

(ii) under aromatic bromination conditions, followed by subsection of the resulting bromo derivative to, respectively,

(a) lithium-bromine exchange, followed by reaction of the aryllithium derivative with ethylene oxide to give the 2-hydroxyethyl derivative, or

(b) reaction with allyl alcohol, followed by catalytic hydrogenation of the alkene to give the 3-hydroxypropyl derivative, or

(c) reaction with 3-buten-1-ol, followed by catalytic hydrogenation of the alkene to give the 4-hydroxybutyl derivative, and optional conversion of any of the foregoing alcohols to the corresponding alkane, amine or nitrile by activation of their respective hydroxy groups to give the chloride or mesylate followed by reduction, or reaction with an amine of formula R⁵R⁶NH, or reaction with an alkali metal cyanide, respectively, and further optional conversion of the said nitrile to the corresponding amide or ester;

(D) C₂-C₄ alkenyl 2-substituted with CN, CONR⁵R⁶ or CO₂R⁷, or C₂-C₄ alkyl 2-substituted with CN, CONR⁵R⁶, CO₂R⁷ or CH₂NH₂, wherein R⁵, R⁶ and R⁷ are as previously defined in this claim,

via the bromo derivative of (C) (ii) above, with the appropriate α, β-unsaturated nitrile, amide or ester respectively, optionally followed by hydrolysis of any resulting ester, reduction of the resulting alkenyl group and, in the case of the nitrile, further or concomitant reduction of the nitrile group to the corresponding primary amine;

(E) C₂-C₄ alkenyl, or C₂-C₄ alkyl, each optionally substituted with CN, CONR⁵R⁶ or CO₂R⁷ wherein R⁵, R⁶ and R⁷ are as previously defined in this claim,

via the bromo derivative of (C) (ii) above, with a lithium-bromine exchange reagent, followed by subsection of the aryllithium derivative to formylation, and reaction of the resulting aldehyde with the appropriate optionally CN-, CONR⁵R⁶- or CO₂R⁷-substituted C₁-C₃ alkyl phosphonium salt or phosphonate, optionally followed by hydrolysis of any resulting ester and reduction of the resulting alkenyl group;

(F) (C₂-C₃ alkoxy)C₁-C₂ alkyl optionally substituted with OH or NR⁵R⁶ wherein R⁵ and R⁶ are as previously defined in this claim,

(i) via the chloromethyl derivative of (C) (i) above, with either

(a) a C₂- or C₃-alcohol, or

(b) a C₂- or C₃-diol, optionally followed by activation of the hydroxy group to give the mesylate and reaction either with an amine of formula R⁵R⁶NH, or with a protected amine of formula R⁵NHP, R⁶NHP or P'₂NH wherein P and P' are as previously defined in this claim; or

(ii) via the bromo derivative of (C) (ii) above, with a lithium-bromine exchange reagent, followed by reaction of the aryllithium derivative with ethylene oxide to give the 2-hydroxyethyl derivative, and activation of the hydroxy group and further reaction as in (i) (a) or (i) (b);

(G) CONR⁵R⁶ or CO₂R⁷ wherein R⁵, R⁶ and R⁷ are as previously defined in this claim,

via the bromo derivative of (C) (ii) above, with a lithium-bromine exchange reagent, followed by

reaction of the aryllithium derivative with carbon dioxide, and conversion of a suitably activated form of the resulting carboxylic acid to an amide or ester derivative by reaction with an amine of formula R^5R^6NH or alcohol of formula R^7OH respectively;

(H) NH_2 , halo, $NHSO_2NR^5R^6$ or $NHSO_2R^8$ wherein halo is fluoro, chloro, bromo or iodo, and R^5 , R^6 and R^8 are as previously defined in this claim,

under aromatic nitration conditions, followed by reduction of the resulting nitro compound to the corresponding primary amine, and subjection of the said amine to, respectively,

(a) a conventional diazotisation-halogenation reaction sequence, or

(b) reaction with either a sulphonyl halide of formula $R^5R^6NSO_2halo$ or a sulphonyl halide of formula R^8SO_2halo , wherein halo is preferably chloro, or reaction with sulphamide when both R^5 and R^6 are H;


(I) phenyl or heterocyclyl, either of which is optionally substituted with methyl, via the bromo derivative of (C) (ii) above, with either

(i) when R^4 is optionally substituted phenyl or C-linked heterocyclyl, the appropriate optionally substituted phenyl or heterocyclyl zincate derivative in the presence of a palladium catalyst, or



(ii) when R^4 is N-linked heterocycle, the appropriate heterocycle in the presence of copper-bronze, iodine and a base;

followed in each case, by optional isolation as, or formation of, a pharmaceutically acceptable salt of the product.

2. A process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 and R^4 are as previously defined in claim 1, which comprises reacting a compound of formula (II), wherein R^3 is H and R^1 and R^2 are as previously defined in claim 1, according to any process defined in claim 1 followed by O-alkylation of the phenolic group to introduce R^3 and optional isolation as, or formation of, a pharmaceutically acceptable salt of the product.
3. A process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 and R^4 are as previously defined in claim 1, which comprises reacting a compound of formula (X):



wherein Y is chloro or bromo, and R^3 and R^4 are as previously defined in claim 1, with an aminopyrazole of either formula (VII) or formula (VIII):



wherein R^1 and R^2 are as previously defined in claim 1, followed by cyclisation of the respective resulting amides by treatment with a base, optionally in the presence of hydrogen peroxide, and optional isolation as, or formation of, a pharmaceutically acceptable salt.

4. A process as claimed in claim 1 wherein in (A), Y is chloro or bromo, the Lewis acid is aluminium chloride or aluminium bromide, and the reducing

agent is sodium borohydride;

in (B), X and Y are chloro or bromo, P is benzyl and is removed by catalytic hydrogenation, and P' is t-butoxycarbonyl and is removed using hydrogen chloride;

in (C),

(i) the chloromethylation is carried out using paraformaldehyde and concentrated hydrochloric acid, and

(a) the reduction is effected by palladium-catalysed hydrogenation,

(b) the alkali metal hydroxide is sodium hydroxide or potassium hydroxide,

(c) the reaction with R^5R^6NH is carried out using an excess of said amine,

(d) the alkali metal cyanide is sodium cyanide or potassium cyanide;

(ii) the aromatic bromination is carried out using N-bromosuccinimide, and

(a) the lithium-bromine exchange is effected using n-butyllithium,

(b) the reaction with allyl alcohol is effected under Heck reaction conditions,

(c) the reaction with 3-buten-1-ol is effected under Heck reaction conditions;

in (D), the reaction with the appropriate α,β -unsaturated nitrile, amide or ester respectively, is effected under Heck reaction conditions using tri-o-tolylphosphine, palladium(II) acetate and triethylamine, the optional hydrolysis of the ester is achieved using aqueous sodium hydroxide solution in methanol, the optional reduction of the alkenyl group is effected by palladium-catalysed hydrogenation, and the optional further or concomitant reduction of the nitrile group is carried out using Raney nickel in glacial acetic acid;

in (E), the lithium-bromine exchange is effected using n-butyllithium, the formylation reagent is dimethylformamide, and the alkene reduction is achieved by catalytic hydrogenation;

in (F), the reaction with

(a) a C_2 - or C_3 -alkanol, is carried out in the presence of one equivalent of sodium metal, or

(b) a C_2 - or C_3 -diol, is carried out in the presence of one equivalent of sodium metal, the hydroxy group is converted to its mesylate using mesyl chloride in pyridine as solvent, and the reaction with R^5R^6NH is carried out using an excess of said amine; and

(ii) the lithium-bromine exchange is effected using n-butyllithium;

in (G), the lithium-bromine exchange is effected using n-butyllithium, and the carboxylic acid is activated using a carbodiimide in combination with 1-hydroxybenzotriazole;

in (H), the nitration is achieved using concentrated nitric acid in combination with concentrated sulphuric acid, the nitro compound is reduced by catalytic hydrogenation, the reaction with a sulphamoyl chloride or with a sulphonyl chloride is carried out in the presence of excess pyridine or triethylamine optionally in the presence of 4-dimethylaminopyridine, and the reaction with sulphamide is effected at about 100°C;

in (I),

(i) the palladium catalyst is tetrakis(triphenylphosphine)palladium(0), and the optionally substituted phenyl or heterocyclyl zincate derivative is obtained from the corresponding optionally substituted phenyl or heterocyclyllithium derivative and anhydrous zinc chloride; and

(ii) the heterocyclic is present in excess, and the base is anhydrous potassium carbonate.

5. A process as claimed in claim 2 wherein the O-alkylation is effected using the appropriate alkyl chloride, bromide or sulphonate, in the presence of potassium carbonate.

6. A process as claimed in any one of claims 1 to 5 wherein R^1 is H, methyl or ethyl; R^2 is C_1 - C_3 alkyl; R^3 is C_2 - C_3 alkyl; R^4 is C_1 - C_2 alkyl optionally substituted with OH, NR^5R^6 , $CONR^5R^6$ or CO_2R^7 ; acetyl optionally substituted with NR^5R^6 ; hydroxyethyl substituted with NR^5R^6 ; ethoxymethyl optionally substituted with OH or NR^5R^6 ; $CH=CHCN$; $CH=CHCONR^5R^6$; $CH=CHCO_2R^7$; CO_2H ; $CONR^5R^6$; Br, NR^5R^6 ; $NHSO_2NR^5R^6$; $NHSO_2R^8$; or pyridyl or imidazolyl either of which is optionally substituted with methyl; R^5 and R^6 are each independently H, methyl or ethyl, or together with the nitrogen atom to which they are attached form a piperidino, morpholino, 4-(NR^9)-1-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or hydroxy; R^7 is H or t-butyl; R^8 is methyl or $CH_2CH_2CH_2NR^5R^6$; and R^9 is H, methyl, benzyl, 2-hydroxyethyl or acetyl.

7. A process as claimed in claim 6 wherein R^1 is methyl; R^2 is n-propyl; R^3 is ethyl or n-propyl; R^4 is $CH_2NR^5R^6$, $CH_2OCH_2CH_2NR^5R^6$, $CH_2OCH_2CH_3$, $CH_2OCH_2CH_2OH$, $COCH_2NR^5R^6$, $CH(OH)CH_2NR^5R^6$, $CH=CHCON(CH_3)_2$, $CH=CHCO_2R^7$, CO_2H , $CONR^5R^6$, Br, $NHSO_2NR^5R^6$, $NHSO_2CH_2CH_2CH_2NR^5R^6$, 2-pyridyl, 1-imidazolyl or 1-methyl-2-imidazolyl; R^5 and R^6 together with the nitrogen atom to which they are at-

tached from a piperidino, 4-hydroxypiperidino, morpholino, 4-(NR⁹)-1-piperazinyl or 2-methyl-1-imidazolyl group; R⁷ is H or t-butyl; and R⁹ is H, methyl, benzyl, 2-hydroxyethyl or acetyl.

8. A process as claimed in claim 7 wherein said compound of formula (I) produced is selected from:

5 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

10 5-[5-(4-acetyl-1-piperazinyl)acetyl-2-ethoxyphenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

and 5-(5-morpholinoacetyl-2-n-propoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and pharmaceutically acceptable salts thereof.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

Application Number

EP 92 30 6137

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
D,X	EP-A-0 201 188 (WARNER-LAMBERT COMPANY) * claims 1,8,9 *	1,5,7	C07D487/04 A61K31/505
P,A	EP-A-0 463 756 (PFIZER) * claims 1,5,7 *	1,5,7	/(C07D487/04, 239:00,231:00)
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
			C07D A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search THE HAGUE		Date of completion of the search 12 OCTOBER 1992	Examiner VOYIAZOGLOU D.
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>* : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>F : intermediate document</p>			

EPO FORM 1303 04.92 (P04107)



EP 92 30 6137 -C-

Remark: Although claim 8 is directed to a method of treatment of (diagnostic method practised on) the human/animal body (Article 52(4) EPC) the search has been carried out and based on the alleged effects of the compound/composition.